GH Research PLC
$21.5
▼
-1.02%
2026-04-21 07:04:01
www.ghres.com
NGM: GHRS
Explore GH Research PLC stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.33 B
Current Price
$21.5
52W High / Low
$24.66 / $8.66
Stock P/E
—
Book Value
$4.51
Dividend Yield
—
ROCE
-21.68%
ROE
-21.04%
Face Value
—
EPS
$-0.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
73
Beta
1
Debt / Equity
0.18
Current Ratio
34.13
Quick Ratio
34.13
Forward P/E
-8.56
Price / Sales
—
Enterprise Value
$694.91 M
EV / EBITDA
-11.47
EV / Revenue
—
Rating
None
Target Price
$39.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aardvark Therapeutics, Inc. | $5.65 | — | $114.1 M | — | -58.82% | -64.44% | $17.94 / $3.35 | $4.89 |
| 2. | Pliant Therapeutics, Inc. | $1.29 | — | $79.87 M | — | -74.87% | -61.55% | $1.95 / $1.09 | $2.95 |
| 3. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
| 4. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 5. | Aptorum Group Limited | $0.9 | — | $7.21 M | — | -12.89% | -10.79% | $4.47 / $0.65 | $2.84 |
| 6. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 7. | Geron Corporation | $1.56 | — | $1.02 B | — | -11.23% | -32.99% | $2.01 / $1.04 | $0.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -16.7 M | -16.54 M | -14.69 M | -12.75 M | -12.92 M | — |
| Net Profit | -14.14 M | -14.02 M | -9.29 M | -10.81 M | -8.8 M | — |
| EPS in Rs | -0.23 | -0.23 | -0.15 | -0.17 | -0.14 | -0.23 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -60.68 M | -50.25 M | -41.22 M | -30.68 M |
| Net Profit | -48.26 M | -38.96 M | -35.59 M | -22.46 M |
| EPS in Rs | -0.78 | -0.63 | -0.57 | -0.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 288.23 M | 188.27 M | 226.3 M | 254.36 M |
| Total Liabilities | 8.53 M | 9.32 M | 7.33 M | 4.55 M |
| Equity | 279.7 M | 178.95 M | 218.97 M | 249.82 M |
| Current Assets | 285.98 M | 154.22 M | 164.09 M | 168.54 M |
| Current Liabilities | 8.38 M | 8.95 M | 6.7 M | 4.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -43.55 M | -42.28 M | -33.34 M | -26.2 M |
| Investing CF | 46.17 M | 65.14 M | -54.1 M | -84.69 M |
| Financing CF | 139.65 M | -0.3 M | -0.2 M | 0 M |
| Free CF | -43.67 M | -42.33 M | -33.44 M | -26.27 M |
| Capex | -0.12 M | -0.05 M | -0.1 M | -0.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -23.86% | -9.48% | -58.47% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.